
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is poised for success with their innovative test, EsoGuard, that has already gained attention and positive coverage from payers. The company is also expanding their market to include higher-risk patients and has received grant funding for research in non-GERD patients, showing the potential for further growth. With a "Buy" rating from a reputable investment firm and promising results, Lucid has a positive outlook for the future.
Bears say
Lucid Diagnostics is a commercial-stage medical diagnostics technology company that focuses on patients at risk of developing esophageal cancer. The company's two main products, EsoGuard and EsoCheck, are expected to receive positive coverage from Medicare in mid-2026, which will likely serve as a catalyst for ramping up commercialization and revenue growth. With multiple growth drivers ahead, including potential commercial payor wins and increased Medicare coverage, Lucid Diagnostics has the potential for significant market growth in the expanding field of esophageal cancer detection.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares